A Phase 3 interventional study of OTX-TKI and Aflibercept in Neovascular Age-related Macular Degeneration, sponsored by Ocular Therapeutix, Inc.. Active, not recruiting at 97 sites in 4 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-06-17.
Sponsored by Ocular Therapeutix, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.
Among the 645 studies in Macular Degeneration with a site in United States, this one is the 27th largest by planned enrollment of the 491 interventional ones that give a count, is one of 24 that started in 2024, is one of 86 in phase 3, reaches primary completion later than 42 of the 124 other live ones, and was the 575th registered.
1,460 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:
Genentech, Inc. · Sites in United States
Ages 50+
Biojiva LLC · Sites in United States, Australia
Ages 55+
Sitala Bio LTD · Sites in United States, Argentina, Australia and 4 more countries
Ages 60+
Scott Raymond · Sites in United States
Ages 50–80
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 6+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 152 · Phase 2 216 · Phase 3 103 · Phase 4 27
First in 1992; this study’s year is marked. 24 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 825 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 55 across the 491 interventional studies, 100 across the 146 observational. Of the 464 that completed or were terminated, 183 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
375 of 645 have an industry lead sponsor. The 10 most frequent:
Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
Ocular Therapeutix, Inc. has 5 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
36 of the studies in Macular Degeneration with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT06495918Phase 3Ocular Therapeutix, Inc.Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration | 2027-01-08 |
| NCT06864988Phase 34D Molecular Therapeutics4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | 2027-06 |
| NCT05904028Phase 3Jaeb Center for Health ResearchHome OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD | 2027-07-30 |
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
Add all 36 to your calendar (.ics) → With an account.
Among the 645 studies in Macular Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age- Related Macular Degeneration
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: OTX-TKI
Drug: Aflibercept
Drug: Aflibercept
Intravitreal Injection of OTX-TKI
Intravitreal Injection of 2mg of aflibercept
Intravitreal Injection of 8mg of aflibercept
Best Corrected Visual Acuity (BCVA)
Mean change in Best Corrected Visual Acuity (BCVA) from baseline at Week 48
Time frame: Week 48
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jan 2027, 25 months after the start.
Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's planned 25 months is close to that.
Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib